officer of the Commission to represent the interests of the general public in these proceedings (Public Representative).

3. Comments are due no later than April 18, 2016.

4. The Secretary shall arrange for publication of this order in the **Federal Register**.

By the Commission.

Stacy L. Ruble,

Secretary.

[FR Doc. 2016–08612 Filed 4–13–16; 8:45 am]

BILLING CODE 7710–FW–P

POSTAL REGULATORY COMMISSION

[Docket Nos. MC2016–120 and CP2016–150; Order No. 3227]

New Postal Product

AGENCY: Postal Regulatory Commission.

ACTION: Notice.

SUMMARY: The Commission is noticing a recent Postal Service filing concerning the addition of Priority Mail Express & Priority Mail Contract 29 to the competitive product list. This notice informs the public of the filing, invites public comment, and takes other administrative steps.

DATES: *Comments are due:* April 18, 2016.

ADDRESSES: Submit comments electronically via the Commission's Filing Online system at *http://www.prc.gov*. Those who cannot submit comments electronically should contact the person identified in the **FOR FURTHER INFORMATION CONTACT** section by telephone for advice on filing alternatives.

FOR FURTHER INFORMATION CONTACT: David A. Trissell, General Counsel, at 202–789–6820.

SUPPLEMENTARY INFORMATION:

Table of Contents

I. Introduction

In accordance with 39 U.S.C. 3642 and 39 CFR 3020.30-.35, the Postal Service filed a formal request and associated supporting information to add Priority Mail Express & Priority Mail Contract 29 to the competitive product list.[1]

The Postal Service contemporaneously filed a redacted contract related to the proposed new product under 39 U.S.C. 3632(b)(3) and 39 CFR 3015.5. Request, Attachment B.

To support its Request, the Postal Service filed a copy of the contract, a copy of the Governors' Decision authorizing the product, proposed changes to the Mail Classification Schedule, a Statement of Supporting Justification, a certification of compliance with 39 U.S.C. 3633(a), and an application for non-public treatment of certain materials. It also filed supporting financial workpapers.

II. Notice of Commission Action

The Commission establishes Docket Nos. MC2016–120 and CP2016–150 to consider the Request pertaining to the proposed Priority Mail Express & Priority Mail Contract 29 product and the related contract, respectively.

The Commission invites comments on whether the Postal Service's filings in the captioned dockets are consistent with the policies of 39 U.S.C. 3632, 3633, or 3642, 39 CFR part 3015, and 39 CFR part 3020, subpart B. Comments are due no later than April 18, 2016. The public portions of these filings can be accessed via the Commission's Web site (*http://www.prc.gov*).

The Commission appoints Curtis E. Kidd to serve as Public Representative in these dockets.

III. Ordering Paragraphs

It is ordered:

1. The Commission establishes Docket Nos. MC2016–120 and CP2016–150 to consider the matters raised in each docket.

2. Pursuant to 39 U.S.C. 505, Curtis E. Kidd is appointed to serve as an officer of the Commission to represent the interests of the general public in these proceedings (Public Representative).

3. Comments are due no later than April 18, 2016.

4. The Secretary shall arrange for publication of this order in the **Federal Register**.

By the Commission.

Stacy L. Ruble,

Secretary.

[FR Doc. 2016–08613 Filed 4–13–16; 8:45 am]

BILLING CODE 7710–FW–P

POSTAL SERVICE

Mail Classification Schedule Changes Pertaining to Priority Mail International Flat Rate Envelopes and Priority Mail International Small Flat Rate Boxes

AGENCY: Postal Service.

ACTION: Notice.

SUMMARY: The Postal Service hereby provides notice that it has filed a request with the Postal Regulatory Commission to change the Mail Classification Schedule provisions that pertain to Priority Mail International Flat Rate Envelopes and Priority Mail International Small Flat Rate Boxes.

DATES: *Effective date:* April 14, 2016.

FOR FURTHER INFORMATION CONTACT: Christopher C. Meyerson, 202–268–7820.

SUPPLEMENTARY INFORMATION: On April 7, 2016, the United States Postal Service® filed with the Postal Regulatory Commission (Commission) a requested change to the Mail Classification Schedule provisions concerning Priority Mail International Flat Rate Envelopes and Priority Mail International Small Flat Rate Boxes. Documents pertinent to this request are available at *http://www.prc.gov,* Docket No. MC2016–118. The Governors' Decision in connection with the above filing is reprinted below.

Stanley F. Mires,

Attorney, Federal Compliance.

Decision of the Governors of the United States Postal Service on Mail Classification Schedule Changes for Priority Mail International Flat Rate Envelopes and Priority Mail International Small Flat Rate Boxes (Governors' Decision No. 16–1)

March 30, 2016

Statement of Explanation and Justification

Pursuant to our authority under section 404(b) and Chapter 36 of title 39, United States Code, the Governors establish classification changes to Priority Mail International Flat Rate Envelopes (PMI FREs) and PMI Small Flat Rate Boxes (PMI SFRBs).

PMI FREs and PMI SFRBs are Postal Service-branded mailing containers available at no additional cost and used by customers to send documents and small merchandise items abroad. Currently, the Postal Service dispatches PMI FREs and PMI SFRBs in the letter post stream, while all other PMI items are dispatched in the parcel post stream. This results in PMI FREs and PMI SFRBs being subject to different market and operational characteristics. The Postal Service intends to change the dispatch stream for PMI FREs and PMI SFRBs to the international parcel post stream. This change would allow PMI FREs and PMI SFRBs to receive expanded access to tracking services and insurance, which are not routinely

[1] Request of the United States Postal Service to Add Priority Mail Express & Priority Mail Contract 29 to Competitive Product List and Notice of Filing (Under Seal) of Unredacted Governors' Decision, Contract, and Supporting Data, April 8, 2016 (Request).

available for ordinary letter post items absent a special arrangement with the destination postal operator. This change will increase delivery costs since foreign postal operators charge higher rates for delivery of parcels as compared to letter post pieces; however, this change will improve the market features of PMI FREs and PMI SFRBs. We have evaluated the classification changes in this context in accordance with 39 U.S.C. 3632–3633 and 39 CFR 3015.5 and 3015.7. We approve the changes, finding that they are appropriate, and are consistent with the regulatory criteria, as indicated by management.

Order

We direct management to file with the Postal Regulatory Commission appropriate notice of these classification changes. The changes in classification set forth herein shall be effective on June 3, 2016.

By The Governors:

James H. Bilbray
Chairman, Temporary Emergency Committee of the Board of Governors

[FR Doc. 2016–08583 Filed 4–13–16; 8:45 am]

BILLING CODE 7710–12–P

REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION

[BAC 416404]

Annual Public Meeting

ACTION: Notice of annual meeting.

SUMMARY: The Reagan-Udall Foundation for the Food and Drug Administration (FDA), which was created by Title VI of the Food and Drug Administration Amendments Act of 2007, is announcing its annual public meeting. The purpose of this meeting is to provide an opportunity for the Foundation to engage with its stakeholders and receive public input on its efforts. The meeting will include an organizational update, project updates, open Q & A and the opportunity for public commentary.

DATES: The public meeting will be held on May 26, 2016, from 10 a.m. until 12 noon. Registration to attend the meeting and requests for oral presentation must be received by May 18, 2016. See the **SUPPLEMENTARY INFORMATION** section for information on how to register for the meeting.

ADDRESSES: The public meeting will be held at 901 E St. NW., Washington, DC 20004. Entrance for the meeting is located on 9th St. NW., between F St. NW. and E St. NW.

FOR FURTHER INFORMATION CONTACT: Dr. Nancy Beck, Reagan-Udall Foundation for the FDA, 202–828–1205, *Meetings@ReaganUdall.org.*

SUPPLEMENTARY INFORMATION:

I. Background

The Reagan-Udall Foundation for the FDA (the Foundation) is an independent 501(c)(3) not-for-profit organization created by Congress to advance the mission of FDA to modernize medical, veterinary, food, food ingredient, and cosmetic product development; accelerate innovation; and enhance product safety. With the ultimate goal of improving public health, the Foundation provides a unique opportunity for different sectors (FDA, patient groups, academia, other government entities, and industry) to work together in a transparent way to create exciting new research projects to advance regulatory science.

The Foundation acts as a neutral third party to establish novel, scientific collaborations. Much like any other independently developed information, FDA evaluates the scientific information from these collaborations to determine how Reagan-Udall Foundation projects can help the Agency to fulfill its mission.

The Foundation's programmatic efforts are designed to improve the existing scientific tools (methods) used to evaluate products as well as foster the development of innovative tools and approaches. This is exemplified in the Foundation's projects including: The Innovation in Medical Evidence Development and Surveillance (IMEDS) Program, which develops and evaluates methods for using observational electronic health care data for postmarket evidence generation, including postmarket safety surveillance; the Big Data for Patients (BD4P) Program, which is a data science training program for patient advocates in the science, concepts, uses, and impact of big data on patients; and the Critical Path to Tuberculosis Drug Regimens Project, which looks at novel approaches to development and review of tuberculosis combination therapies, including strategies for engaging communities in the research process. The Foundation is currently exploring potential new projects as well. One of those projects is the Food Safety Innovation Consortium, to advance regulatory science in the food safety arena. Another area under development involves examining ways to improve the availability and clarity of information on the request process for individual expanded access (compassionate use) for drugs that have not yet been approved by the FDA.

II. Meeting Attendance and Participation

A. Registration

If you wish to attend the meeting, visit: *http://bit.ly/1RRSqjp.* Please register for the meeting by May 18, 2016. Seating is limited and registration will be on a first-come, first-served basis. Onsite registration will be available if space permits. There is no fee to attend this workshop.

B. Requests for Oral Comments

Interested persons are welcome to present comments at the public meeting, provided they are submitted by May 18, 2016. Comments are scheduled to begin approximately at 11:40 a.m. Time allotted for comments may be limited to 3 minutes, dependent upon the number of requests received. Submissions must include: Your name, organization, address, telephone number, email, and a brief statement on the general nature of your comments. All submissions should be sent to: *comments@reaganudall.org,* please specify ''RUF Public Meeting Comments'' in the subject line.

The agenda for the public meeting will be posted on the event page on the Reagan-Udall Web site: *http://bit.ly/1UZnfcb.*

C. Written Comments

Interested persons may submit either electronic or written comments to the Foundation at any time to *comments@reaganudall.org,* or by mail to the Reagan-Udall Foundation for the FDA, 1025 Connecticut Ave. NW., Suite 1000, Washington, DC 20036. Please include your name, organization, address, telephone number, and email when making comments.

III. Post-Meeting Materials

The Foundation plans to make meeting materials and meeting recording available to the public after the meeting. Once available, these materials will be posted on the Reagan-Udall Web site: *http://bit.ly/1UZnfcb.*

Dated: April 11, 2016.

Nancy Beck,

Acting Deputy Director, Reagan-Udall Foundation for the FDA.

[FR Doc. 2016–08656 Filed 4–13–16; 8:45 am]

BILLING CODE 4164–04–P